Products/Services Used | Details | Operation |
---|---|---|
Mutagenesis Services> | M. abscessus and M. chelonae ClpC1 plasmids were obtained from Genscript (Piscataway, NJ) using M. tuberculosis clpC2 as a DNA template for mutagenesis. | Get A Quote |
ClpC1 is an emerging new target for the treatment of infections, and several cyclic peptides (ecumicin, cyclomarin A, and lassomycin) are known to act on this target. This study identified another group of peptides, the rufomycins (RUFs), as bactericidal to through the inhibition of ClpC1 and subsequent modulation of protein degradation of intracellular proteins. Rufomycin I (RUFI) was found to be a potent and selective lead compound for both (MIC, 0.02 μM) and (MIC, 0.4 μM). Spontaneously generated mutants resistant to RUFI involved seven unique single nucleotide polymorphism (SNP) mutations at three distinct codons within the -terminal domain of (V13, H77, and F80). RUFI also sign... More